{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T15:34:32Z","timestamp":1773070472335,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T00:00:00Z","timestamp":1513123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.ymgmr.2017.12.002","type":"journal-article","created":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T16:17:56Z","timestamp":1514391476000},"page":"55-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Mildly elevated succinylacetone and normal liver function in compound heterozygotes with pathogenic and pseudodeficient FAH alleles"],"prefix":"10.1016","volume":"14","author":[{"given":"Hao","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8896-1468","authenticated-orcid":false,"given":"Francis","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Cyr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Laframboise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu Pei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Soucy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Th\u00e9r\u00e8se","family":"Berthier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Gigu\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4898-1859","authenticated-orcid":false,"given":"Paula J.","family":"Waters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grant A.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgmr.2017.12.002_bb0005","series-title":"In The Online Metabolic & Molecular Bases of Inherited Disease (OMMBID)","first-page":"1777","article-title":"Tanguay RM: Hypertyrosinemia","author":"Mitchell","year":"2001"},{"key":"10.1016\/j.ymgmr.2017.12.002_bb0010","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1750-1172-8-8","article-title":"Recommendations for the management of tyrosinaemia type 1","volume":"8","author":"de Laet","year":"2013","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2017.12.002_bb0015","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2012.05.022","article-title":"Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Quebec","volume":"107","author":"Larochelle","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2017.12.002_bb0020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ymgme.2014.07.010","article-title":"Succinylacetone as primary marker to detect tyrosinemia type I in newborns and its measurement by newborn screening programs","volume":"113","author":"De Jesus","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2017.12.002_bb0025","doi-asserted-by":"crossref","first-page":"S296","DOI":"10.1542\/peds.2005-2633I","article-title":"Newborn screening: toward a uniform screening panel and system\u2014executive summary","volume":"117","author":"Watson","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgmr.2017.12.002_bb0030","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.clinbiochem.2004.07.006","article-title":"Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spots","volume":"37","author":"Allard","year":"2004","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ymgmr.2017.12.002_bb0035","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jchromb.2005.12.007","article-title":"MS validated method for the nanomolar range determination of succinylacetone in amniotic fluid and plasma: an analytical tool for tyrosinemia type I","volume":"832","author":"Cyr","year":"2006","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.ymgmr.2017.12.002_bb0040","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1056\/NEJM199408113310603","article-title":"A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I","volume":"331","author":"Grompe","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgmr.2017.12.002_bb0045","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/jmedgenet-2016-104289","article-title":"Hypersuccinylacetonaemia and normal liver function in maleylacetoacetate isomerase deficiency","volume":"54","author":"Yang","year":"2017","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgmr.2017.12.002_bb0050","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0009-8981(85)90102-0","article-title":"Concentrations of succinylacetone after homogentisate and tyrosine loading in healthy individuals with low fumarylacetoacetase activity","volume":"152","author":"Kvittingen","year":"1985","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgmr.2017.12.002_bb0055","first-page":"1122","article-title":"Identification of a frequent pseudodeficiency mutation in the fumarylacetoacetase gene, with implications for diagnosis of tyrosinemia type I","volume":"55","author":"Rootwelt","year":"1994","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgmr.2017.12.002_bb0060","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-3-319-55780-9_17","article-title":"The Quebec NTBC study","volume":"959","author":"Quebec NTBC Study Group","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ymgmr.2017.12.002_bb0065","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJM199002153220704","article-title":"Neurologic crises in hereditary tyrosinemia","volume":"322","author":"Mitchell","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgmr.2017.12.002_bb0070","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2017.12.002_bb0075","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1203\/00006450-199201000-00008","article-title":"Hereditary tyrosinemia type I: lack of correlation between clinical findings and amount of immunoreactive fumarylacetoacetase protein","volume":"31","author":"Kvittingen","year":"1992","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgmr.2017.12.002_bb0080","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJM198305263082105","article-title":"Evidence for liver disease preceding amino acid abnormalities in hereditary tyrosinemia","volume":"308","author":"Hostetter","year":"1983","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgmr.2017.12.002_bb0085","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2012-006301","article-title":"Corneal depositions in tyrosinaemia type I during treatment with Nitisinone","volume":"2012","author":"Wisse","year":"2012","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.ymgmr.2017.12.002_bb0090","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10545-011-9394-5","article-title":"Neurocognitive outcome in patients with hypertyrosinemia type I after long-term treatment with NTBC","volume":"35","author":"Thimm","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2017.12.002_bb0095","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-3-319-55780-9_10","article-title":"Neurological and neuropsychological problems in tyrosinemia type I patients","volume":"959","author":"van Ginkel","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ymgmr.2017.12.002_bb0100","doi-asserted-by":"crossref","first-page":"210","DOI":"10.4212\/cjhp.v68i3.1454","article-title":"Cost-consequence analysis of nitisinone for treatment of tyrosinemia type I","volume":"68","author":"Simoncelli","year":"2015","journal-title":"Can. J. Hosp. Pharm."},{"issue":"12","key":"10.1016\/j.ymgmr.2017.12.002_bb0105","doi-asserted-by":"crossref","DOI":"10.1038\/gim.2017.101","article-title":"Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations","volume":"19","author":"Chinsky","year":"2017","journal-title":"Genet. Med."}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426917301635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426917301635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:49:35Z","timestamp":1762001375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426917301635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":21,"alternative-id":["S2214426917301635"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2017.12.002","relation":{},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mildly elevated succinylacetone and normal liver function in compound heterozygotes with pathogenic and pseudodeficient FAH alleles","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2017.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}